

New Topical Drug in Development Targets the HPV Virus in Warts; CBCD Reviews a Report

A preliminary study has shown that the experimental drug Ranpirnase can completely clear the warts caused by HPV. (1)

ROCHESTER, NEW YORK, UNITED STATES, June 14, 2015
/EINPresswire.com/ --

“Infected with the human papillomavirus (HPV)? The CBCD recommends taking [Gene-Eden-VIR](#) or [Novirin](#).” - Greg Bennett, CBCD

There may be good news on the horizon for those with genital warts. An experimental drug called Ranpirnase has been shown to be effective against the human papillomavirus (HPV) in early clinical trials. (1) Dr. Eric Daniels, MD, said that “Current treatments can destroy the warts, but the warts can return ... (Ranpirnase) is absorbed by human cells, shuts down RNA synthesis, and prevents viruses from replicating.” (1) If the drug passes further trials, Ranpirnase will be the first drug approved against the HPV.

In the study, Ranpirnase was provided to patients as a topical lotion. The lotion was used on genital warts. Thus, the drug targets the HPV virus in the warts themselves, and is not a systemic drug. In other words, it does not target the latent virus, or the active virus everywhere else.

Because Ranpirnase is still in early clinical trials, it is still not approved by the FDA for use against genital warts. There are currently no drugs approved against the HPV. “Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus. The procedures do not target cells with the



procedures only produce a temporary remission.” (2) Until Ranpirnase, or a drug like it, is approved by the FDA and enters the market, the Center for the Biology of Chronic Disease (CBCD) recommends Gene-Eden-VIR or Novirin to those with genital warts. The formula of these natural antiviral products was shown to reduce symptoms associated with HPV in two separate post-marketing clinical studies that followed FDA guidelines.

Click to learn more about [HPV symptoms](#).

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD. The studies showed that the formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HPV...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (2) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (2)

Both products can be ordered online on the Gene-Eden-VIR and Novirin websites here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses.

To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims. Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

During the study mentioned above, “The researchers offered (a) lotion to adults with external genital and perianal HPV warts. They instructed the patients to apply the lotion twice a day. Patients were evaluated once a week for 8 weeks.” (1) At visit 4 (of weekly visits) “four of the patients (30.8%) had no warts, six (46.2%) had a 50% improvement, and three (23.1%) had a 25% improvement. At week 8, none of the patients who returned for evaluation had any warts. All had achieved a complete remission.” (1)

Ranpirnase is designed to fight the active HPV within the warts. In contrast, Novirin and Gene-Eden-VIR were designed to help the immune system target the latent HPV everywhere in the body.

Individuals interested in viewing published studies on the formula of Novirin and Gene-Eden-VIR can go here:

<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U-s9ouOSz90>

and

<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234#.U-s9w-OSz90>

All orders of Gene-Eden-VIR and Novirin are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

- (1) Harrison, L. "Antiviral Promising in Early HPV Trial" Published March 23, 2015. - Medscape.com
- (2) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8<http://dx.doi.org/10.4236/pp.2013.46A001>

Hanan Polansky
Lilac Corp.
5852509999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2015 IPD Group, Inc. All Right Reserved.



